Recently, the Phase I clinical trials for a new type of vaccine, "Influenza Virus Subunit Vaccine (Adjuvant)", and "Tetravalent Influenza Virus Subunit Vaccine (Adjuvant)", jointly applied for by Yither Biotech (Shanghai) Co., Ltd (Yither Bio) and its company Ab&B Bio-Tech Co.,Ltd (Ab&B Bio), have been successfully initiated in Hubei. These two vaccine research and development achievements are steadily translating into company performance, and also mark a solid step forward in the company's subunit influenza vaccine product pipeline towards providing the most precise coverage for people of different ages and needs.

Currently, influenza virus remains one of the significant respiratory pathogens threatening human public health. Seasonal influenza outbreaks or occasional cross-species transmission and pandemics of influenza virus have a substantial impact on human health and socio-economic aspects. Compared to other age groups, the elderly have a higher infection rate, and a greater risk of severe illness and death after contracting influenza, which increases with age. Both the World Health Organization (WHO) and the Chinese Center for Disease Control and Prevention recommend that the elderly be one of the priority groups for influenza vaccination.
The adjuvanted influenza virus subunit vaccine is a product developed by the company in response to the vaccination needs of different populations and the WHO's recommendations for influenza vaccination. Utilizing the company's mature platform technology and novel adjuvants, this vaccine is specifically designed for the elderly population aged 65 and above. Preclinical studies have shown that the adjuvanted influenza virus subunit vaccine can significantly enhance the body's antibody level and neutralizing antibody titer, demonstrating notable advantages in enhancing immune response capabilities. It provides the optimal choice for the elderly population to combat influenza.